PARP/EZH2-IN-1

• UNSPSC Description:

  PARP/EZH2-IN-1 is a first-in-class dual PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.

• Target Antigen:

  Histone Methyltransferase; PARP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/parp-ezh2-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=C(C(NC(C)=O)=CC(C2=CC=C(N=C2)N3CCN(CC3)C(C4=CC(CC5=NNC(C6=C5C=CC=C6)=O)=CC=C4F)=O)=C1)C)NCC7=C(C=C(NC7=O)C)C

• Molecular Weight:

  768.83

• References & Citations:

  [1]Wang C, et al. Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA. J Med Chem. 2021 Sep 9;64(17):12630-12650.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2687273-52-3